PureTech Health Plc has appointed Robert Lyne as chief executive officer after serving as interim CEO since July 2025. Mr Lyne joined PureTech in January 2024 as chief portfolio officer. As CEO he will focus initially on securing funding for PureTech’s newest founded entity, Celea Therapeutics, following a successful end-of-phase 2 meeting with the US Food and Drug Administration, and will also pursue financing in 2026 for Gallop Oncology as the programme advances to the next stage of development.
PureTech is a ‘hub-and-spoke’ biotherapeutics company which develops a pipeline of therapeutic candidates through dedicated structures backed by external capital. Three have received FDA approval. Mr Lyne was previously CEO of Arix Bioscience and has been involved in over 80 venture capital financings across Europe and North America as well as multiple portfolio exits and initial public offerings.
PureTech Health announced the appointment on 18 December 2025.
Copyright 2026 Evernow Publishing Ltd.